Novartis has signed an agreement with Alteogen that could be worth up to $3.22bn for the development and commercialisation of subcutaneous drug formulations using Alteogen’s ALT-B4 technology.

Typewriter harnesses a non-viral approach as viral vectors increasingly come under the spotlight for their associated safety risks.

The FDA's latest efforts to curb the illicit US medicines trade are primarily centred around weight loss and fat-reducing peptides.

Eli Lilly has once again returned to the M&A table, striking a $2.875bn agreement to buy autoimmune and allergic disease drug developer Merida Biosciences. The deal for Merida, wh ...

Several treatment guidelines worldwide recommend the use of SGLT2 inhibitors as a treatment for all types of heart failure.

Researchers call for further exploration of xylitol’s impact on heart health as its use in food and pharma continues to rise.

The US FDA has approved PharmaEssentia’s Besremi (ropeginterferon alfa-2b-njft) to treat adults with essential thrombocythaemia (ET).

The Australia-based STAREE trial is the first of its kind demonstrating the preventative effects of statins in older patients.

The new Mounjaro approval will likely expand Lilly’s cardiometabolic empire as it looks to stay ahead of rival Novo Nordisk.

Aficamten improves cardiac structure and diastolic function, strengthening its case as a targeted therapy for nonobstructive HCM.

Study shows that those with low adherence of blood pressure-lowering drugs had significantly impaired therapeutic effect.

ReviR Therapeutics has received a RPDD from the US FDA for RTX-117, its investigational oral small-molecule therapy for CMT.